000131583 001__ 131583
000131583 005__ 20240228145607.0
000131583 0247_ $$2doi$$a10.1007/s00117-017-0297-9
000131583 0247_ $$2pmid$$apmid:28875369
000131583 0247_ $$2ISSN$$a0033-832X
000131583 0247_ $$2ISSN$$a1432-2102
000131583 0247_ $$2altmetric$$aaltmetric:24898295
000131583 037__ $$aDKFZ-2017-06215
000131583 041__ $$ager
000131583 082__ $$a610
000131583 1001_ $$0P:(DE-He78)1464357f7ec5faf677a390a414e50c88$$aHeining, Christoph$$b0$$eFirst author$$udkfz
000131583 245__ $$a[Personalized oncology].
000131583 260__ $$aBerlin$$bSpringer$$c2017
000131583 3367_ $$2DRIVER$$aarticle
000131583 3367_ $$2DataCite$$aOutput Types/Journal article
000131583 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1521466290_11799$$xReview Article
000131583 3367_ $$2BibTeX$$aARTICLE
000131583 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000131583 3367_ $$00$$2EndNote$$aJournal Article
000131583 520__ $$aInnovative next generation sequencing (NGS) technologies and comprehensive sequencing investigations in large patient cohorts have paved the way for very promising personalized treatment strategies based on the molecular characteristics of individual tumors.Targeted therapies, such as tyrosine kinase inhibitors, antibodies and modern immunotherapeutic approaches are well established as monotherapy and combination therapy for many hematological and oncological malignancies.A plethora of innovative therapies targeting various components of intracellular signaling cascades and effective mechanisms against oncogenes as well as the availability of NGS technologies enable personalized cancer treatment based on the molecular profiles of individual tumors and genetic stratification, within clinical trials.Comprehensive genetic approaches including cancer gene panel sequencing, whole exome, whole genome and transcriptome sequencing are carried out to a varying extent and particularly in the academic setting.Principally, a comprehensive characterization of tumors in addition to DNA and RNA sequencing that also incorporates epigenetic, metabolomic, and proteomic alterations would be desirable. A comprehensive clinical implementation of integrative, multidimensional genetic typing is, however, currently not possible.It remains to be demonstrated whether these approaches will translate into significantly better outcomes for patients and whether they can be increasingly implemented in the routine diagnostic work-up.The selection of diagnostic tools in individual cases and the extent of genomic analyses in the clinical context, need to take the availability of methods as well as the present clinical situation into account.
000131583 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000131583 588__ $$aDataset connected to CrossRef, PubMed,
000131583 7001_ $$0P:(DE-He78)5ea1944c122bc098a81df27a05572719$$aHorak, P.$$b1$$udkfz
000131583 7001_ $$0P:(DE-He78)5120a331b1c28045c8ca6a8b1c73c95f$$aGröschel, S.$$b2$$udkfz
000131583 7001_ $$0P:(DE-He78)157277fe62f07df1732f9d126a51d1b9$$aGlimm, H.$$b3$$udkfz
000131583 7001_ $$0P:(DE-He78)f0144d171d26dbedb67c9db1df35629d$$aFröhling, Stefan$$b4$$eLast author$$udkfz
000131583 773__ $$0PERI:(DE-600)1463036-9$$a10.1007/s00117-017-0297-9$$gVol. 57, no. 10, p. 804 - 811$$n10$$p804 - 811$$tDer Radiologe$$v57$$x1432-2102$$y2017
000131583 909CO $$ooai:inrepo02.dkfz.de:131583$$pVDB
000131583 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)1464357f7ec5faf677a390a414e50c88$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000131583 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5ea1944c122bc098a81df27a05572719$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000131583 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5120a331b1c28045c8ca6a8b1c73c95f$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000131583 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)157277fe62f07df1732f9d126a51d1b9$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000131583 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f0144d171d26dbedb67c9db1df35629d$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000131583 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000131583 9141_ $$y2017
000131583 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000131583 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bRADIOLOGE : 2015
000131583 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000131583 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000131583 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000131583 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000131583 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000131583 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000131583 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000131583 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000131583 9201_ $$0I:(DE-He78)G100-20160331$$kG100$$lTranslationale Onkologie$$x0
000131583 9201_ $$0I:(DE-He78)G240-20160331$$kG240$$lMolekulare Leukämogenese$$x1
000131583 980__ $$ajournal
000131583 980__ $$aVDB
000131583 980__ $$aI:(DE-He78)G100-20160331
000131583 980__ $$aI:(DE-He78)G240-20160331
000131583 980__ $$aUNRESTRICTED